ID: ALA3321939

Max Phase: Preclinical

Molecular Formula: C28H36BrFN4O5

Molecular Weight: 607.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(CNC(=O)[C@@H](CC2CCCCC2)NC(=N)NC(=O)Cc2cc(OC)c(OC)cc2Br)ccc1F

Standard InChI:  InChI=1S/C28H36BrFN4O5/c1-37-23-12-18(9-10-21(23)30)16-32-27(36)22(11-17-7-5-4-6-8-17)33-28(31)34-26(35)14-19-13-24(38-2)25(39-3)15-20(19)29/h9-10,12-13,15,17,22H,4-8,11,14,16H2,1-3H3,(H,32,36)(H3,31,33,34,35)/t22-/m1/s1

Standard InChI Key:  ASRZOKKKEGIGOW-JOCHJYFZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 607.52

Molecular Weight (Monoisotopic): 606.1853

AlogP: 4.45

#Rotatable Bonds: 11

Polar Surface Area: 121.77

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.52

CX Basic pKa: 7.97

CX LogP: 4.56

CX LogD: 3.89

Aromatic Rings: 2

Heavy Atoms: 39

QED Weighted: 0.22

Np Likeness Score: -0.63

References

1. Grädler U, Czodrowski P, Tsaklakidis C, Klein M, Werkmann D, Lindemann S, Maskos K, Leuthner B..  (2014)  Structure-based optimization of non-peptidic Cathepsin D inhibitors.,  24  (17): [PMID:25086681] [10.1016/j.bmcl.2014.07.054]

Source

Source(1):

• Scientific Literature